MHC

Cat. No.

A35341

CAS No.

656831-18-4

Pam2Cys

Synonyms: Dipalmitoyl-S-glyceryl-cysteine; S-[2,3-Bis(palmitoyloxy)propyl]cysteine

Pam2Cys is a TLR2 agonist that acts as an immunostimulant by binding to TLR2, activating dendritic cells, and initiating the TLR2-dependent NF-κB signaling pathway. This compound promotes dendritic cell maturation through the upregulation of MHC II molecules, enhances innate immune signaling, and drives pro-inflammatory responses, including the release of IL-12 and other cytokines. Additionally, Pam2Cys serves as a lipid moiety in synthetic lipopeptide vaccines, boosting immunogenicity, while selectively inducing pro-inflammatory macrophage activation. Research applications include studies on tuberculosis and influenza A virus infections, as it effectively recruits immune cells and mitigates infection-related symptoms without compromising adaptive immunity.

Cat. No.

A60388

CAS No.

60320-05-0

Cholic acid 7-sulfate

Synonyms: 7-Sulfocholic acid

Cholic acid 7-sulfate is a selective agonist for the TGR5 receptor with an EC50 of 0.17 μM. This compound enhances GLP-1 secretion in enteroendocrine L cells, leading to improved glucose tolerance through TGR5 activation. Additionally, as an endogenous ligand for MHC class I-related protein (MR1), it supports the survival of mucosal-associated invariant T (MAIT) cells and influences their development and function by modulating homeostatic gene expression. Cholic acid 7-sulfate is valuable in studies related to diabetes and MAIT cell-mediated immune regulation.

Cat. No.

A76520

CAS No.

79066-03-8

DMHCA

DMHCA is a potent and selective liver X receptor (LXR) agonist that specifically activates the cholesterol efflux pathway while avoiding the stimulation of triglyceride synthesis. This compound exhibits anti-inflammatory properties, making it a valuable tool for research in cholesterol homeostasis and diabetes. DMHCA's selective mechanism provides insight into the role of LXR modulation in metabolic disorders.

Cat. No.

B18104

CAS No.

147245-92-9

Glatiramer acetate

Glatiramer acetate is a synthetic analogue of myelin basic protein that functions primarily as an immune modulator for the treatment of multiple sclerosis. Its mechanism involves inhibiting experimental autoimmune encephalomyelitis (EAE) by competing with myelin antigens for binding to MHC molecules, which subsequently modulates T cell response. Additionally, glatiramer acetate promotes the induction of T helper 2 (Th2) cells, which migrate to the central nervous system and facilitate localized immunosuppression. This compound serves as a valuable tool for research into autoimmune disorders and therapeutics for multiple sclerosis.